Activation profiles of opioid ligands in HEK cells expressing δ opioid receprtors

BMC Neuroscience

Volumn 3, Issue , 2002, Pages

  Gharagozlou, Parham ^a   Demirci, Hasan ^a   Clark, J David ^b   Lameh, Jelveh ^a  

^a MOLECULAR RESEARCH INSTITUTE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTORPHANOL; CYCLAZOCINE; CYCLIC AMP; DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR AGONIST; DELTA OPIATE RECEPTOR ANTAGONIST; DEZOCINE; ETORPHINE; FENTANYL; FORSKOLIN; HYDROMORPHONE; LIGAND; LOFENTANIL; METAZOCINE; METENKEPHALIN; MORPHINE; N ALLYLNORMETAZOCINE; NALBUPHINE; NALORPHINE; NALTREXONE; OPIATE DERIVATIVE; QUADAZOCINE; UNCLASSIFIED DRUG; XORPHANOL;

ARTICLE; BINDING AFFINITY; CELL STRAIN; CONTROLLED STUDY; DATA ANALYSIS; DRUG ACTIVATION; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; EMBRYO CELL; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; KIDNEY CELL; PROTEIN EXPRESSION;

EID: 2642566190     PISSN: 14712202     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2202-3-19     Document Type: Article

References (35)

1. Reisine T, Bell GI: Molecular biology of opioid receptors. Trends Neurosci 1993, 16:506-510
2. Dhawan BN, Cesselin F, Raghubir R, Reisine T, Bradley PB, Portoghese PS, Hamon M: International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol Rev 1996, 48:567-592
3. Abdelhamid EE, Sultana M, Portoghese PS, Takemori AE: Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. J Pharmacol Exp Ther 1991, 258:299-303
4. Filizola M, Villar HO, Loew GH: Molecular determinants of non-specific recognition of delta, mu, and kappa opioid receptors. Bioorg Med Chem 2001, 9:69-76
5. Filizola M, Villar HO, Loew GH: Differentiation of delta, mu, and kappa opioid receptor agonists based on pharmacophore development and computed physicochemical properties. J Comput Aided Mol Des 2001, 15:297-307
6. Reisine T, Pasternak G: Opioid Analgesics and Antagonists. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics (Edited by: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG) New York: McGraw-Hill Companies 1996, 521-549
7. Prather PL, Song L, Piros ET, Law PY, Hales TG: delta-Opioid receptors are more efficiently coupled to adenylyl cyclase than to L-type Ca(2+) channels in transfected rat pituitary cells. J Pharmacol Exp Ther 2000, 295:552-562
8. Wang JF, Ren MF, Xue JC, Han JS: Cyclic AMP mediates mu and delta, but not kappa opioid analgesia in the spinal cord of the rat. Life Sci 1993, 52:1955-1960
9. Mantegazza P, Tammiso R, Zambotti F, Zecca L, Zonta N: Purine involvement in morphine antinociception. Br J Pharmacol 1984, 83:883-888
10. Pasternak GW: Pharmacological mechanisms of opioid analgesics. Clin Neuropharmacol 1993, 16:1-18
11. Brandt MR, Furness MS, Mello NK, Rice KC, Negus SS: Antinociceptive effects of delta-opioid agonists in Rhesus monkeys: effects on chemically induced thermal hypersensitivity. J Pharmacol Exp Ther 2001, 296:939-946
12. Kovelowski CJ, Bian D, Hruby VJ, Lai J, Ossipov MH, Porreca F: Selective opioid delta agonists elicit antinociceptive supraspinal/spinal synergy in the rat. Brain Res 1999, 843:12-17
13. Takita K, Herlenius EA, Lindahl SG, Yamamoto Y: Actions of opioids an respiratory activity via activation of brainstem mu-delta- and kappa-receptors; an in vitro study. Brain Res 1997, 778:233-241
14. Negus SS, Picker MJ: Pharmacology of the nonpeptide delta opioid agonist BW373U86. CNS Drug Rev 1996, 2:68-90
15. Dykstra LA, Schoenbaum GM, Yarbrough J, McNutt R, Chang KJ: A novel delta opioid agonist, BW373U86, in squirrel monkeys responding under a schedule of shock titration. J Pharmacol Exp Ther 1993, 267:875-882
16. Wild KD, McCormick J, Bilsky EJ, Vanderah T, McNutt RW, Chang KJ, Porreca F: Antinociceptive actions of BW373U86 in the mouse. J Pharmacol Exp Ther 1993, 267:858-865
17. Schiller PW, Fundytus ME, Merovitz L, Weltrowska G, Nguyen TM, Lemieux C, Chung NN, Coderre TJ: The opioid mu agonist/delta antagonist DIPP-NH(2)[Psi] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats. J Med Chem 1999, 42:3520-3526
18. Wells JL, Bartlett JL, Ananthan S, Bilsky EJ: In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence. J Pharmacol Exp Ther 2001, 297:597-605
19. Gutstein HB, Akil H: Opioid Analgesics. In: Goodman & Gilman's the pharmacological basis of therapeutics (Edited by: Goodman LS, Hardman JG, Limbird LE, Gilman AG) New York: McGraw-Hill, Medical Pub. Division 2001
20. Davis PJ, Cook DR: Clinical pharmacokinetics of the newer intravenous anaesthetic agents. Clin Pharmacokinet 1986, 11:18-35
21. Clark MJ, Emmerson PJ, Mansour A, Akil H, Woods JH, Portoghese PS, Remmers AE, Medzihradsky F: Opioid efficacy in a C6 glioma cell line stably expressing the delta opioid receptor. J Pharmacol Exp Ther 1997, 283:501-510
22. Malatynska E, Wang Y, Knapp RJ, Waite S, Calderon S, Rice K, Hruby VJ, Yamamura HI, Roeske WR: Human delta opioid receptor: functional studies on stably transfected Chinese hamster ovary cells after acute and chronic treatment with the selective nonpeptidic agonist SNC-80. J Pharmacol Exp Ther 1996, 278:1083-1089
23. Raynor K, Kong H, Chen Y, Yasuda K, Yu L, Bell GI, Reisine T: Pharmacological characterization of the cloned kappa-, delta-,and mu-opioid receptors. Mol Pharmacol 1994, 45:330-334
24. Toll L, Berzetei-Gurske IP, Polgar WE, Brandt SR, Adapa ID, Rodriguez L, Schwartz RW, Haggart D, O'Brien A, White A, Kennedy JM, Craymer K, Farrington L, Auh JS: Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res Monogr 1998, 178:440-466
25. Fu MJ, Tsen LY, Lee TY, Lui PW, Chan SH: Involvement of cerulospinal glutamatergic neurotransmission in fentanyl-induced muscular rigidity in the rat. Anesthesiology 1997, 87:1450-1459
26. Jaros T, Kolasiewicz W: Attenuation of the fentanyl-induced muscle rigidity by the selective 5HT1A agonist 8-OH-DPAT. Pol J Pharmacol 1995, 47:19-24
27. Tsou MY, Lui PW, Lee TY, Pan JT, Chan SH: Differential effects of prazosin and yohimbine on fentanyl-induced muscular rigidity in rats. Neuropharmacology 1989, 28:1163-1168
28. Lui PW, Lee TY, Chan SH: Involvement of locus coeruleus and noradrenergic neurotransmission in fentanyl-induced muscular rigidity in the rat. Neurosci Lett 1989, 96:114-119
29. Viscomi CM, Bailey PL: Opioid-induced rigidity after intravenous fentanyl. Obstet Gynecol 1997, 89:822-824
30. Howes JF, Villarreal JE, Harris LS, Essigmann EM, Cowan A: Xorphanol. Drug Alcohol Depend 1985, 14:373-380
31. McCarthy PS, Howlett GJ: Physical dependence induced by opiate partial agonists in the rat. Neuropeptides 1984, 5:11-14
32. Cruz SL, Villarreal JE, Volkow ND: Further evidence that naloxone acts as an inverse opiate agonist: implications for drug dependence and withdrawal. Life Sci 1996, 58:PL381-389
33. Arden JR, Segredo V, Wang Z, Lameh J, Sadée W: Phosphorylation and agonist-specific intracellular trafficking of an epitope-tagged μ-opioid receptor expressed in HEK 293 cells. Journal of Neurochemistry 1995, 65:1636-1645
34. Lameh J, Wang P, Elgart D, Meredith D, Shafer SL, Loew GH: Unraveling the Identity of Benzodiazepine Binding Sites in Rat Hippocampus and Olfactory Bulb. European Journal of Pharmacology 2000, 400:167-176
35. Lameh J, Keohane A, Clark DJ, Loew GH: Characterization of Novel Benzodiazepine ligands in Sf-9 cells. Neurosci Lett 2001, 306:25-28